HIV-Target Cell Response in Women Initiating Various Contraceptive Methods in High HIV-Incidence Areas: Zim CHIC
NCT ID: NCT02038335
Last Updated: 2020-12-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
451 participants
OBSERVATIONAL
2014-02-28
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Immune cells will be studied from the reproductive tract of women who want to start using one of the following contraceptives: Depo-Provera (DMPA), NET-EN, MPA/E2 (Cyclofem®), the levonorgestrel subdermal implant (Jadelle® ), the etonogestrel subdermal implant (Implanon® or Nexplanon® ) and the copper IUD.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DMPA
Depot medroxyprogesterone acetate
DMPA
Depot medroxyprogesterone acetate
NET-EN
Norethisterone enantate
NET-EN
Norethisterone enantate
MPA/E2
Medroxyprogesterone acetate and estradiol cypionate
MPA/E2
Medroxyprogesterone acetate and estradiol cypionate
LNG-I
Levonorgestrel subdermal implant
LNG-I
Levonorgestrel subdermal implant
ENG-I
Etonogestrel subdermal implant
ENG-I
Etonogestrel subdermal implant
Cu-IUD
Copper IUD
Cu-IUD
Copper IUD
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DMPA
Depot medroxyprogesterone acetate
NET-EN
Norethisterone enantate
MPA/E2
Medroxyprogesterone acetate and estradiol cypionate
LNG-I
Levonorgestrel subdermal implant
ENG-I
Etonogestrel subdermal implant
Cu-IUD
Copper IUD
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Non-pregnant women in general good health as determined by the site clinician
* Premenopausal with history of regular menstrual cycles (regular cycles defined as occurring every 21-35 days when not using hormones and with a variation of typical cycle length of no more than 5 days)
* Able and willing to provide written informed consent to be screened for and to take part in the study. Including willingness to undergo all study-related assessments and follow all study-related procedures
* Able and willing to provide adequate locator information
* HIV-uninfected based on testing performed by study staff at screening
* At screening and enrollment, agrees not to participate in other research studies involving drugs, medical devices, or vaginal products while enrolled in this trial
Exclusion Criteria
* Use of DMPA or NET-EN within 10 months of enrollment
* Pregnancy or breastfeeding within 60 days of enrollment
* Surgical procedure involving the pelvis in the 30 days prior to enrollment (includes dilation and curettage, cryosurgery and biopsy of the vagina, vulva, cervix, and endometrium)
* Internal vaginal use of any device (includes sex toys, cervical caps, diaphragms, menstrual collection devices, and pessaries; excludes tampons and condoms) or product (includes N9, microbicide, douche, antifungal, steroid, or hormone) in the 30 days prior to enrollment
* New sexual partner within 90 days of enrollment
* Urogenital infection or suspected infection within 30 days of enrollment including:
symptomatic candidiasis, trichomoniasis, and symptomatic BV; or cervical infection, including N. gonorrhoeae, Chlamydia trachomatis, or mucopurulent cervicitis; syphilis; HSV lesions, or other sores (Note: seropositive HSV without active lesions will not be excluded); acute pelvic inflammatory disease; urinary tract infection; recent exposure to a partner with GC, CT, Trichomonas, syphilis, or NGU. Women who have had diagnosed genital infections should have completed treatment at least 30 days before the time of enrollment.
* Any history of immunosuppression (includes diabetes, HIV infection, and chronic steroid use)
* Antibiotic or antifungal therapy (vaginal or systemic) within 30 days of enrollment
* Menses or other vaginal bleeding at the time of Enrollment\* (\*Women who have vaginal bleeding at the scheduled Enrollment Visit may return at a different date to be re-examined and possibly enrolled provided they are still within the 90-day screening window and meet all criteria).
* Vaginal or anal intercourse within 2 days (48 hours) prior to enrollment
* Heterosexual intercourse since last menses that places the participant at risk of pregnancy (without condom use or sterilization of at least one partner)
* History of hysterectomy
* History of malignancy within the pelvis (includes uterus, cervix, vagina, and vulva)
* Contraindication, allergy or intolerance to use of the contraceptive desired by the participant
* Any condition that, in the opinion of the Investigator, would preclude provision of consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives
18 Years
34 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Zimbabwe
OTHER
University of Pittsburgh
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sharon Achilles
Principal Investigator and Protocol Chair
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sharon Achilles, MD, PhD
Role: STUDY_CHAIR
University of Pittsburgh
Felix Mhlanga, MD
Role: PRINCIPAL_INVESTIGATOR
University of Zimbabwe, University of California San Francisco
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UZ UCSF
Harare, , Zimbabwe
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Achilles SL, Meyn LA, Mhlanga FG, Matubu AT, Stoner KA, Beamer MA, Chirenje ZM, Hillier SL. Zim CHIC: A cohort study of immune changes in the female genital tract associated with initiation and use of contraceptives. Am J Reprod Immunol. 2020 Sep;84(3):e13287. doi: 10.1111/aji.13287. Epub 2020 Jun 25.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRO13080550
Identifier Type: -
Identifier Source: org_study_id